Aurobindo Pharma Q2 FY25 net profit up 8.6% at Rs. 817 Cr
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
This product will be manufactured at Lupin’s Nagpur facility in India
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range
Subscribe To Our Newsletter & Stay Updated